huntingtons disease epidemiology forecast insight

DelveInsight’s ‘Huntington’s Disease (HD) - Epidemiology Forecast to 2034’ report delivers an in-depth understanding of the disease, historical and forecasted Huntington’s Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2021-2034

Huntington’s Disease (HD) Understanding

Huntington’s Disease (HD) is a rare, incurable, genetic, progressive neurodegenerative disorder that causes brain cells, termed as neurons, to die in several areas of the brain, together with those that help control voluntary (intentional) movement. It is passed on (inherited) from a person’s parents and known to get worse over time, disturbing the patient’s physical movements, emotions, and cognitive abilities. Huntington’s Disease is caused by an error in the DNA commands that build our bodies and keep them running. DNA is made up of thousands of genes, and people with Huntington’s Disease have a small fault in one gene, chromosome 4 – one of the 23 human chromosomes that carry a person’s entire genetic code. This defect is “dominant,” meaning that any person who inherits it from a parent with Huntington’s will develop the disease in the long run. The faulty gene codes the blueprint for a protein called huntingtin. This protein’s normal function is not yet known; however, it is called “huntingtin” because scientists acknowledged its defective form as the cause of Huntington’s Disease. Over time, this defective huntingtin protein leads to brain changes that cause abnormal involuntary movements, a severe decline in thinking and reasoning skills, and irritability, depression, and other mood changes. Huntington’s Disease symptoms can develop at any time, but they often first appear when people are in their 30s or 40s. The only cause behind the occurrence of Huntington’s Disease is a faulty gene that results in parts of the brain gradually becoming impaired over time. It is inherited as an autosomal dominant trait. A person is generally only at risk of developing it if one of the parents has or had it. In dominant disorders, a single copy of the disease gene (received from either the mother or father) will be expressed “dominating” the other normal gene and resulting in the appearance of the disease.

Epidemiology Perspective by DelveInsight

The Huntington’s Disease epidemiology division provides the insights about historical and current Huntington’s Disease patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

In 2020, the overall prevalent cases of Huntington’s Disease accessed to be around 80,170 in the 7MM, which are expected to grow during the forecast period, i.e., 2025-2034.

The disease epidemiology covered in the report provides historical as well as forecasted Huntington’s Disease epidemiology segmented as [Total Prevalent cases of Huntington’s Disease, Total Diagnosed Prevalent cases of Huntington’s Disease, Huntington’s Disease cases by age, Huntington’s Disease cases by Stage, and Total treated cases of Huntington’s Disease] in the 7MM, covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2021 to 2034.

Country Wise- Huntington’s Disease Epidemiology

• In the United States, the total number of prevalent cases of Huntington’s Disease were 42,414 in 2020, which are expected to increase during the forecast period, i.e., 2025-2034.
• In 2020, the total prevalent cases of Huntington’s Disease were 35,930 in EU-5, which are projected to increase during the forecast period, i.e., 2025-2034.
• Findings from various secondary studies suggest that Huntington’s Disease is more prevalent in elderly population.
• In addition, secondary data suggest that less people identified in stage IV and stage V with Huntington's disease. In 2020, 3,195 Stage IV cases of Huntington’s Disease and 777 Stage V cases of Huntington’s Disease were estimated for the 7MM.

Scope of the Report

• The Huntington’s Disease report covers a detailed overview explaining its causes, symptoms, and pathophysiology, diagnosis, and treatment patterns.
• The Huntington’s Disease Report and Model provide an overview of the risk factors and global trends of Huntington’s Disease in the seven major markets (7MM: United States, Germany, France, Italy, Spain, and the United Kingdom, and Japan)
• The report provides insight about the historical and forecasted patient pool of Huntington’s Disease in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of HUNTINGTON’S DISEASE .
• The report provides the segmentation of the Huntington’s Disease epidemiology by total prevalent cases in the 7MM.
• The report provides the segmentation of the Huntington’s Disease epidemiology by diagnosed prevalent cases in the 7MM.
• The report provides the segmentation of the Huntington’s Disease epidemiology by age-specific diagnosed prevalent cases in the 7MM.
• The report provides the segmentation of the Huntington’s Disease epidemiology by stage-specific diagnosed prevalent cases of Huntington’s Disease in the 7MM.
• The report provides the segmentation of the Huntington’s Disease epidemiology by treated cases of Huntington’s Disease in the 7MM.

Report Highlights

• 10-Year Forecast of Huntington’s Disease epidemiology
• 7MM Coverage
• Epidemiology Segmentation

KOL-Views

We interview, KOL’s and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the over Huntington’s Disease scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Huntington’s Disease?
• What are the key findings pertaining to the Huntington’s Disease epidemiology across the 7MM and which country will have the highest number of patients during the study period (2021-2034)?
• What would be the total number of patients of Huntington’s Disease across the 7MM during the study period (2021-2034)?
• Among the EU5 countries, which country will have the highest number of patients during the study period (2021-2034)?
• At what CAGR the patient population is expected to grow in the 7MM during the study period (2021-2034)?
• What are the various recent and upcoming events which are expected to improve the diagnosis of Huntington’s Disease ?

Reasons to buy

The Huntington’s Disease Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Huntington’s Disease market
• Quantify patient populations in the global Huntington’s Disease market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and gender that present the best opportunities for Huntington’s Disease therapeutics in each of the markets covered
• Understand the magnitude of Huntington’s Disease population by its severity
• The Huntington’s Disease epidemiology report and model were written and developed by Masters and Huntington’s Disease level epidemiologists
• The Huntington’s Disease Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 10-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population